Talk to usTalk to us
Language: EN
Talk to us

Press

  1. Baladna Q.P.S.C.: Profit Before Portfolio Gains Up 20% in Nine Months

  2. Baladna Q.P.S.C.: The Raise, the Costs and the Half Year

  3. Zaptec ASA: The Share Price Now Pays for the Chargers, Not Yet for the Service on Them

  4. Sirnaomics Ltd.: The RNAimmune Money Is In, and the FDA Has Answered in Writing on STP705

  5. Ainos, Inc.: A Partner Pays for VELDONA, and Ainos Keeps the Platform

  6. Ainos Inc: A Front-End Customer Starts Ordering, and the Dataset Passes a Billion

  7. Ainos, Inc.: Three Patents Approved in Japan, and a Dataset Gathering Pace

  8. Baladna: The Capital Is Raised, Algeria Is Building – VASRO Reiterates BUY at QAR 2.33

  9. Sirnaomics Ltd.: Every Approved siRNA Drug Works in the Liver. This One Was Injected Into Skin Cancer. VASRO Initiates Coverage With BUY

  10. Zaptec ASA: Europe’s Largest AC Charging Brand, With the Service Layer Priced at Zero – VASRO Initiates Coverage With BUY